{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:33:05Z","timestamp":1789831985892,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","award":["JPMH23FC1015"],"award-info":[{"award-number":["JPMH23FC1015"]}],"id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic disease with a poor prognosis. As there were no specific biomarkers for diagnosing PSC, we developed diagnostic criteria in 2016 based on cholangiography and elevated biliary enzymes. Novel findings and knowledge have subsequently accumulated, and we now propose the 2024 diagnostic criteria, to overcome several limitations of the 2016 diagnostic criteria. The Intractable Hepato-Biliary Diseases Study Group in Japan of the Committee of Research on Measures for Intractable Diseases established a working group consisting of experts in PSC comprising gastroenterologists, endoscopists, hepatologists, liver-transplant surgeons, pediatric hepatologists, pathologists, and radiologists. This working group proposed the 2024 diagnostic criteria after several discussions and public hearings. There are additional diagnostic targets; small duct PSC, pediatric PSC, and PSC recurrence following liver transplantation differ from the 2016 diagnostic criteria, which were for diagnosing large duct PSC in adults. The 2024 diagnostic criteria facilitate the use of magnetic resonance cholangiography in addition to endoscopic retrograde cholangiography in imaging, and incorporate gamma-glutamyl transferase for evaluating cholestasis to diagnose pediatric patients. Furthermore, PSC recurrence following liver transplantation can be diagnosed based on a liver biopsy and characteristic biliary findings. We hope that the 2024 diagnostic criteria will help not only hepatologists treating adults but also general physicians, pediatric hepatologists, and liver-transplant surgeons who manage patients with various forms of PSC.<\/jats:p>","DOI":"10.1007\/s00535-025-02265-5","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:51:21Z","timestamp":1749707481000},"page":"1221-1231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The 2024 diagnostic criteria for primary sclerosing cholangitis"],"prefix":"10.1007","volume":"60","author":[{"given":"Itaru","family":"Naitoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3308-9326","authenticated-orcid":false,"given":"Hiroyuki","family":"Isayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Umetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Notohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tazuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2265_CR1","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weism\u00fcller","year":"2017","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152:1975-84.e8.","journal-title":"Gastroenterology"},{"issue":"9904","key":"2265_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013;382(9904):1587\u201399.","journal-title":"Lancet"},{"key":"2265_CR3","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045\u201355.","journal-title":"Hepatology"},{"key":"2265_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","volume":"102","author":"JJ Tischendorf","year":"2007","unstructured":"Tischendorf JJ, Hecker H, Kr\u00fcger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107\u201314.","journal-title":"Am J Gastroenterol"},{"key":"2265_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jhbp.432","volume":"24","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci. 2017;24:217\u201325.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2265_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","volume":"57","author":"T Arizumi","year":"2022","unstructured":"Arizumi T, Tazuma S, Isayama H, et al. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. J Gastroenterol. 2022;57:902\u201312.","journal-title":"J Gastroenterol"},{"key":"2265_CR7","unstructured":"Schiff\u2019s Disease of the Liver. 9th ed. Philadelphia: JB Lippincott; 2003. p. 673\u201384."},{"key":"2265_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00535-016-1286-x","volume":"52","author":"T Nakazawa","year":"2017","unstructured":"Nakazawa T, Notohara K, Tazuma S, et al. The 2016 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol. 2017;52:838\u201344.","journal-title":"J Gastroenterol"},{"key":"2265_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","volume":"21","author":"A Tanaka","year":"2014","unstructured":"Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci. 2014;21:43\u201350.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"3","key":"2265_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/jhbp.194","volume":"22","author":"A Tanaka","year":"2015","unstructured":"Tanaka A, Tazuma S, Okazaki K, et al. Clinical profiles of patients with primary sclerosing cholangitis in the elderly. J Hepatobiliary Pancreat Sci. 2015;22(3):230\u20136.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2265_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/hepr.13342","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49:881\u20139.","journal-title":"Hepatol Res"},{"key":"2265_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646\u201359 (quiz 60).","journal-title":"Am J Gastroenterol"},{"key":"2265_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","volume":"53","author":"H Isayama","year":"2018","unstructured":"Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol. 2018;53:1006\u201334.","journal-title":"J Gastroenterol"},{"key":"2265_CR14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356\u201378.","journal-title":"Gut"},{"key":"2265_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-2008-1040417","volume":"11","author":"J Ludwig","year":"1991","unstructured":"Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis. 1991;11:11\u20137.","journal-title":"Semin Liver Dis"},{"key":"2265_CR16","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1007\/s00261-020-02572-w","volume":"45","author":"K Kozaka","year":"2020","unstructured":"Kozaka K, Sheedy SP, Eaton JE, et al. Magnetic resonance imaging features of small-duct primary sclerosing cholangitis. Abdom Radiol (NY). 2020;45:2388\u201399.","journal-title":"Abdom Radiol (NY)"},{"key":"2265_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109101","volume":"129","author":"KI Ringe","year":"2020","unstructured":"Ringe KI, Bergquist A, Lenzen H, et al. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol. 2020;129: 109101.","journal-title":"Eur J Radiol"},{"key":"2265_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","volume":"161","author":"CY Ponsioen","year":"2021","unstructured":"Ponsioen CY, Assis DN, Boberg KM, et al. Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process. Gastroenterology. 2021;161:1764\u20135.","journal-title":"Gastroenterology"},{"key":"2265_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.29204","volume":"66","author":"MR Deneau","year":"2017","unstructured":"Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology. 2017;66:518\u201327.","journal-title":"Hepatology"},{"key":"2265_CR20","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/hepr.13421","volume":"49","author":"S Umetsu","year":"2019","unstructured":"Umetsu S, Notohara K, Nakazawa T, et al. Long-term outcomes of pediatric-onset primary sclerosing cholangitis: a single-center experience in Japan. Hepatol Res. 2019;49:1386\u201397.","journal-title":"Hepatol Res"},{"key":"2265_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2005.10.007","volume":"4","author":"AE Berstad","year":"2006","unstructured":"Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006;4:514\u201320.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2265_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1148\/radiol.10091953","volume":"256","author":"M Dave","year":"2010","unstructured":"Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256:387\u201396.","journal-title":"Radiology"},{"key":"2265_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0016-5107(04)02229-1","volume":"60","author":"T Nakazawa","year":"2004","unstructured":"Nakazawa T, Ohara H, Sano H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc. 2004;60:937\u201344.","journal-title":"Gastrointest Endosc"},{"key":"2265_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/jgh.12894","volume":"30","author":"I Naitoh","year":"2015","unstructured":"Naitoh I, Nakazawa T, Hayashi K, et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis. J Gastroenterol Hepatol. 2015;30:1104\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"2265_CR25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/ibd.22938","volume":"18","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"2265_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.32773","volume":"77","author":"MJ Hole","year":"2023","unstructured":"Hole MJ, J\u00f8rgensen KK, Holm K, et al. A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. Hepatology. 2023;77:715\u201328.","journal-title":"Hepatology"},{"key":"2265_CR27","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41467-023-39029-9","volume":"14","author":"M Ichikawa","year":"2023","unstructured":"Ichikawa M, Nakamoto N, Kredo-Russo S, et al. Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nat Commun. 2023;14:3261.","journal-title":"Nat Commun"},{"key":"2265_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","volume":"58","author":"H Yoshida","year":"2023","unstructured":"Yoshida H, Shiokawa M, Kuwada T, et al. Anti-integrin \u03b1v\u03b26 autoantibodies in patients with primary sclerosing cholangitis. J Gastroenterol. 2023;58:778\u201389.","journal-title":"J Gastroenterol"},{"key":"2265_CR29","unstructured":"Elsevier, Philadelphia, PA, USA, 2023. pp. 1458\u20131496."},{"issue":"Suppl 1","key":"2265_CR30","first-page":"43","volume":"13","author":"J Ludwig","year":"1989","unstructured":"Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol. 1989;13(Suppl 1):43\u20139.","journal-title":"Am J Surg Pathol"},{"key":"2265_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0046-8177(88)80150-3","volume":"19","author":"Y Nakanuma","year":"1988","unstructured":"Nakanuma Y, Yamaguchi K, Ohta G, et al. Pathologic features of hepatolithiasis in Japan. Hum Pathol. 1988;19:1181\u20136.","journal-title":"Hum Pathol"},{"key":"2265_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","volume":"145","author":"JE Eaton","year":"2013","unstructured":"Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521\u201336.","journal-title":"Gastroenterology"},{"key":"2265_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.v18.i1.1","volume":"18","author":"B Fosby","year":"2012","unstructured":"Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18:1\u201315.","journal-title":"World J Gastroenterol"},{"key":"2265_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.15148","volume":"49","author":"IC Steenstraten","year":"2019","unstructured":"Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, et al. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019;49:636\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"2265_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/hep.21280","volume":"44","author":"AJ Demetris","year":"2006","unstructured":"Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489\u2013501.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02265-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:01:55Z","timestamp":1758438115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02265-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT is an advisor of Kaken Pharmaceutical Co Ltd., Kowa Company and GSK. AT received honorariums from Gilead Sciences. No other authors have a conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}